Mesoblast Announces Closing of Initial Public Offering

On November 19, 2015, Australia-based regenerative medicine leader Mesoblast Limited announced the closing of its initial public offering of 8,535,059 American Depositary Shares (ADSs) at a price to the public of $8.00 per ADS. Total gross proceeds were approximately $68.3 million before the deduction of underwriting discounts and commissions and expenses. The company's ADSs began trading on the Nasdaq Global Market on November 13 under the ticker symbol "MESO." Wilson Sonsini Goodrich & Rosati represented Mesoblast in the offering.

J.P. Morgan and Credit Suisse acted as the joint book-running managers and the representatives of the underwriters. Maxim Group LLC and Ladenburg Thalmann acted as co-managers.

The WSGR team that represented Mesoblast in the offering was led by partner Jeff Saper and included partner Steve Bernard, as well as associates Megan Baier, Ava Zhao, and Andrew Ellis. Skadden, Arps, Slate, Meagher & Flom represented the underwriters in the transaction, led by partner Thomas Ivey and associates Sara Terheggen, Shannon Kung, and Mary Boland.

For more information, please see Mesoblast's press release.